跳至主要内容
临床试验/NCT02060357
NCT02060357已完成不适用

Comparison of Two New Generation Drug Eluting Stents in Patients With Diabetes

Barts & The London NHS Trust2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2011年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
2
主要终点
Endothelial stent coverage

研究概览

简要总结

The aim of this study is a comparative evaluation of re-endothelailisation of the Integrity Resolute zotarolimus eluting stent (Medtronic) and of the Promus Element erolimus eluting stent (Boston Scientific), in patients with diabetes.

We plan to compare endothelial coverage and neointimal proliferation using OCT and compare this data to published results from conventional stents.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Known to have diabetes
  • Scheduled for percutaneous coronary intervention (PCI) with a stenosis suitable for DES implantation and OCT imaging
  • Reference vessel diameter over 2.5mm by operator assessment.
  • Able to understand and sign the written Informed Consent Form.
  • Able and willing to follow the Protocol requirements.

排除标准

  • Inability to consent
  • Cardiogenic shock
  • Planned use of a bare metal stent
  • LMS coronary artery disease
  • Congestive cardiac failure or low ejection fraction (LVEF <35%)
  • Lesions unsuitable for OCT
  • Total length of stented lesion greater than 55mm (total combination of stent lengths)
  • Age less than 18 years or age greater than 80 years
  • Planned surgical procedure ≤ 12 months post PCI procedure
  • Patient demonstrates evidence of thrombocytopenia (platelet count < 100,000/mm3)
  • Patients with contraindications to ASA, clopidogrel, or prasogrel
  • Patient is currently on warfarin, or possibility of treatment with warfarin during the following 12 months post index procedure
  • Allergy to contrast
  • Patients enrolled in another active clinical trial.
  • Potential for non-compliance towards the requirements in the study protocol.
  • Serious known concomitant disease with a life expectancy of less than one year
  • Follow-up impossible (no fixed abode, etc)
  • Patients with renal impairment (Creatinine >200mmol/L)
  • Subjects of childbearing potential

结局指标

主要结局

Endothelial stent coverage

时间窗: 6 month

Endothelial coverage expressed as % of struts without coverage as measured by OCT

次要结局

  • Neointimal hyperplasia(6 month)
  • MACE(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anthony Mathur

Professor

Barts & The London NHS Trust

研究点 (2)

Loading locations...

相似试验